Geulah Livshits Analyst PerformanceSenior Research Analyst, Biotech at Chardan CapitalGeulah Livshits is a stock analyst at Chardan Capital focused in the medical sector, covering 30 publicly traded companies. Over the past year, Geulah Livshits has issued 84 stock ratings, including and buy recommendations. While full access to Geulah Livshits' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Geulah Livshits' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings207 Last 7 YearsBuy Recommendations98.55% 204 Buy RatingsCompanies Covered30 Unique Companies Ratings Distribution207RatingsDistribution of strong buy, buy, hold, and sell ratings by Geulah Livshits.RatingPercentageCount Strong Buy0.0%0 ratings Buy98.6%204 ratings Hold1.4%3 ratings Sell0.0%0 ratingsOut of 207 total stock ratings issued by Geulah Livshits at Chardan Capital, the majority (98.6%) have been Buy recommendations, followed by 1.4% Hold.Best & Worst CallsBest Call0000.0%MRNAFeb 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%VINCDec 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ96.7% of companies on NASDAQ29 companiesOTCMKTS3.3% of companies on OTCMKTS1 companyGeulah Livshits, an analyst at Chardan Capital, currently covers 30 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical28 companies93.3%Manufacturing1 company3.3%Retail/Wholesale1 company3.3%Geulah Livshits of Chardan Capital specializes in stock coverage within the Medical sector, with additional focus on Manufacturing and Retail/Wholesale companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE21 companies70.0%MED - DRUGS4 companies13.3%PHARMACEUTICAL PREPARATIONS2 companies6.7%MED - GENERIC DRG1 company3.3%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company3.3%CATALOG & MAIL - ORDER HOUSES1 company3.3% About Geulah LivshitsDr. Geulah Livshits is a Senior Research Analyst at Chardan covering biotech companies, with a focus on gene editing and oncology. Dr. Geulah Livshits joined Chardan in the spring of 2018, after a career as an academic scientist. Prior to joining Chardan, Dr. Livshits was a Postdoctoral Research Fellow in the laboratory of Dr. Scott Lowe at Memorial Sloan Kettering Cancer Center, where she developed CRISPR and RNAi approaches to study pancreatic cancer in vivo and in organoid models. Dr. Livshits conducted her thesis research in the laboratory of Dr. Elaine Fuchs at The Rockefeller University, where she studied mechanisms of skin development and regeneration. Her doctoral and postdoctoral work has been published in peer-reviewed academic journals including Nature, Nature Medicine, Nature Biotechnology, eLife, PNAS, and Human Gene Therapy. Dr. Livshits received her BS from Brandeis University, her PhD from The Rockefeller University, and was a Postdoctoral Research Fellow at Memorial Sloan Kettering Cancer Center.Follow on LinkedIn Geulah Livshits' Ratings History at Chardan Capital Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsRCKTRocket Pharmaceuticals5/11/2026Reiterated Rating$3.63$11.00Buy$0.0000.00% ROILXEOLexeo Therapeutics5/11/2026Reiterated Rating$5.97$17.00Buy$0.0000.00% ROIIOVAIovance Biotherapeutics5/7/2026Lower Price Target$3.55$14.00Buy$0.0000.00% ROICLYMClimb Bio5/5/2026Initiated Coverage$9.69$22.00Buy$0.0000.00% ROIEDITEditas Medicine5/5/2026Boost Price Target$3.04$4.00Buy$0.0000.00% ROINTLAIntellia Therapeutics4/27/2026Boost Price Target$13.92$30.00Buy$0.0000.00% ROIIOVAIovance Biotherapeutics4/10/2026Reiterated Rating$3.67$16.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics3/31/2026Boost Price Target$124.65$240.00Buy$0.0000.00% ROISNTISenti Biosciences3/30/2026Lower Price Target$0.79$11.00Buy$0.0000.00% ROIRCKTRocket Pharmaceuticals3/27/2026Reiterated Rating$3.77$11.00Buy$0.0000.00% ROITomorrow's Stock of the Day (Ad)Looking for better stock ideas? Sign-up to receive The Early Bird Stock of the Day. Each day, MarketBeat's team of expert research analysts identifies one compelling stock and provides both a bull case and a bear case for each company.Get The Early Bird's Stock of the Day (Free)SLDBSolid Biosciences3/20/2026Reiterated Rating$7.12$15.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics3/19/2026Reiterated Rating$8.72$26.00Buy$0.0000.00% ROITSHATaysha Gene Therapies3/19/2026Reiterated Rating$4.56$12.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics3/16/2026Reiterated Rating$126.89$210.00Buy$0.0000.00% ROISLDBSolid Biosciences3/12/2026Reiterated Rating$7.72$15.00Buy$0.0000.00% ROITNYATenaya Therapeutics3/12/2026Reiterated Rating$0.86$8.00Buy$0.0000.00% ROIEDITEditas Medicine3/9/2026Reiterated Rating$2.31$3.50Buy$0.0000.00% ROINTLAIntellia Therapeutics2/27/2026Reiterated Rating$14.28$26.00Buy$0.0000.00% ROIIOVAIovance Biotherapeutics2/25/2026Lower Price Target$3.78$16.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics2/24/2026Boost Price Target$119.55$210.00Buy$0.0000.00% ROIKRYSKrystal Biotech2/18/2026Boost Price Target$287.84$323.00Buy$0.0000.00% ROICRSPCRISPR Therapeutics2/14/2026Boost Price Target$53.07$76.00Buy$0.0000.00% ROIPASGPassage Bio2/10/2026Initiated Coverage$8.90$21.00Buy$0.0000.00% ROILXEOLexeo Therapeutics1/13/2026Reiterated Rating$8.12$17.00Buy$0.0000.00% ROITSHATaysha Gene Therapies1/6/2026Reiterated Rating$5.21$12.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics12/18/2025Reiterated Rating$9.21$26.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics12/15/2025Boost Price Target$88.98$174.00Buy$0.0000.00% ROITNYATenaya Therapeutics12/12/2025Lower Price Target$1.36$8.00Buy$0.0000.00% ROILXEOLexeo Therapeutics12/11/2025Reiterated Rating$9.73$17.00Buy$0.0000.00% ROISNTISenti Biosciences12/9/2025Boost Price Target$1.75$13.00Buy$0.0000.00% ROICRSPCRISPR Therapeutics11/26/2025Lower Price Target$53.57$74.00Buy$0.0000.00% ROIIMTXImmatics11/24/2025Reiterated Rating$10.70$25.00Buy$0.0000.00% ROIIMRXImmuneering11/13/2025Reiterated Rating$6.62$20.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics11/13/2025Reiterated Rating$81.54$110.00Buy$0.0000.00% ROIPASGPassage Bio11/12/2025Boost Price Target$7.70$21.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics11/11/2025Boost Price Target$10.17$26.00Buy$0.0000.00% ROIPRMEPrime Medicine11/10/2025Lower Price Target$3.81$9.00Buy$0.0000.00% ROITNYATenaya Therapeutics11/10/2025Reiterated Rating$1.46$9.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics11/7/2025Boost Price Target$77.17$110.00Buy$0.0000.00% ROINTLAIntellia Therapeutics11/7/2025Lower Price Target$9.52$26.00Buy$0.0000.00% ROIBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you? (Ad)BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset. The reason is tied to a legal mandate - the Clarity Act now requires the entire $382 trillion financial system to move onto a new monetary infrastructure by April 2027. BlackRock CEO Larry Fink calls it 'the next major evolution in market infrastructure.' Every transaction on this new grid burns one specific scarce digital resource - and institutions are accumulating shares before prices move.Discover the asset BlackRock, JPMorgan and Goldman are buying nowIOVAIovance Biotherapeutics11/6/2025Lower Price Target$2.31$17.00Buy$0.0000.00% ROITSHATaysha Gene Therapies11/5/2025Reiterated Rating$4.27$12.00Buy$0.0000.00% ROILXEOLexeo Therapeutics11/5/2025Reiterated Rating$8.20$17.00Buy$0.0000.00% ROISLDBSolid Biosciences11/4/2025Reiterated Rating$5.20$15.00Buy$0.0000.00% ROIKRYSKrystal Biotech11/4/2025Boost Price Target$197.85$220.00Buy$0.0000.00% ROINTLAIntellia Therapeutics10/27/2025Lower Price Target$14.21$48.00Buy$0.0000.00% ROITSHATaysha Gene Therapies10/17/2025Reiterated Rating$5.08$12.00Buy$0.0000.00% ROIRCKTRocket Pharmaceuticals10/14/2025Reiterated Rating$4.26$11.00Buy$0.0000.00% ROILXEOLexeo Therapeutics10/7/2025Boost Price Target$8.30$17.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics9/26/2025Boost Price Target$57.69$73.00Buy$0.0000.00% ROIIMRXImmuneering9/26/2025Boost Price Target$8.00$20.00Buy$0.0000.00% ROIKRYSKrystal Biotech8/22/2025Lower Price Target$145.70$216.00Buy$0.0000.00% ROIRCKTRocket Pharmaceuticals8/20/2025Reiterated Rating$3.43$11.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics8/15/2025Boost Price Target$46.10$60.00Buy$0.0000.00% ROIMGXMetagenomi8/15/2025Lower Price Target$1.86$11.00Buy$0.0000.00% ROILXEOLexeo Therapeutics8/15/2025Lower Price Target$4.72$15.00Buy$0.0000.00% ROISLDBSolid Biosciences8/14/2025Reiterated Rating$6.10$15.00Buy$0.0000.00% ROIIMRXImmuneering8/14/2025Reiterated Rating$3.04$13.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics8/12/2025Reiterated Rating$5.53$25.00Buy$0.0000.00% ROITSHATaysha Gene Therapies8/12/2025Boost Price Target$2.91$10.00Buy$0.0000.00% ROINTLAIntellia Therapeutics8/11/2025Lower Price Target$10.79$60.00Buy$0.0000.00% ROIRCKTRocket Pharmaceuticals8/11/2025Lower Price Target$2.86$11.00Buy$0.0000.00% ROIIOVAIovance Biotherapeutics8/8/2025Lower Price Target$2.64$20.00Buy$0.0000.00% ROIPRMEPrime Medicine8/8/2025Lower Price Target$3.79$10.00Buy$0.0000.00% ROISNTISenti Biosciences8/8/2025Reiterated Rating$1.58$12.00Buy$0.0000.00% ROITNYATenaya Therapeutics8/7/2025Reiterated Rating$0.67$9.00Buy$0.0000.00% ROIKRYSKrystal Biotech8/5/2025Reiterated Rating$134.94$219.00Buy$0.0000.00% ROICRSPCRISPR Therapeutics8/5/2025Reiterated Rating$55.59$82.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics8/1/2025Reiterated Rating$4.50$25.00Buy$0.0000.00% ROIKRYSKrystal Biotech7/25/2025Reiterated Rating$150.00$219.00Buy$0.0000.00% ROIRCKTRocket Pharmaceuticals7/24/2025Lower Price Target$3.21$12.00Buy$0.0000.00% ROIIOVAIovance Biotherapeutics7/23/2025Reiterated Rating$3.13$25.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics7/3/2025Reiterated Rating$4.31$25.00Buy$0.0000.00% ROICRSPCRISPR Therapeutics6/26/2025Reiterated Rating$46.39$82.00Buy$0.0000.00% ROIPASGPassage Bio6/24/2025Reiterated Rating$6.70$120.00Buy$0.0000.00% ROIIMRXImmuneering6/18/2025Reiterated Rating$1.82$13.00Buy$0.0000.00% ROISNTISenti Biosciences6/12/2025Reiterated Rating$2.81$12.00Buy$0.0000.00% ROITSHATaysha Gene Therapies5/29/2025Boost Price Target$2.44$9.00Buy$0.0000.00% ROIRCKTRocket Pharmaceuticals5/28/2025Lower Price Target$2.33$17.00Buy$0.0000.00% ROISLDBSolid Biosciences5/19/2025Lower Price Target$2.77$15.00Buy$0.0000.00% ROIPRMEPrime Medicine5/19/2025Lower Price Target$1.29$12.00Buy$0.0000.00% ROIRCKTRocket Pharmaceuticals5/16/2025Boost Price Target$6.72$46.00Buy$0.0000.00% ROIIPSCCentury Therapeutics5/16/2025Lower Price Target$0.56$6.00Buy$0.0000.00% ROIMGXMetagenomi5/15/2025Lower Price Target$1.50$12.00Buy$0.0000.00% ROILXEOLexeo Therapeutics5/13/2025Lower Price Target$2.63$20.00Buy$0.0000.00% ROINTLAIntellia Therapeutics5/9/2025Reiterated Rating$8.28$68.00Buy$00.0000.00% ROITNYATenaya Therapeutics5/9/2025Reiterated Rating$0.44$9.00Buy$0.0000.00% ROIIOVAIovance Biotherapeutics5/9/2025Lower Price Target$1.76$25.00Buy$0.0000.00% ROIRCKTRocket Pharmaceuticals5/9/2025Lower Price Target$6.97$45.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics5/9/2025Lower Price Target$3.08$25.00Buy$00.0000.00% ROIOil is settling in yuan now - here's what that means for gold (Ad)Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every country on Earth to hold U.S. dollars to buy oil. Since then, Saudi Arabia has signed a $7 billion currency swap with China, begun settling oil in digital yuan, and joined China's cross-border payment system, mBridge. With 10-year Treasury yields pushing toward the 4.4% danger line and global dollar demand in retreat, gold is being repriced. There's one asset that still trades at a steep discount to gold's current price - a rare opportunity to leverage the metal's continued rise.Learn how to position ahead of the dollar's continued declineKRYSKrystal Biotech5/7/2025Reiterated Rating$139.47$219.00Buy$000.0000.00% ROICRSPCRISPR Therapeutics5/7/2025Lower Price Target$33.21$82.00Buy$00.0000.00% ROIIMRXImmuneering5/6/2025Reiterated Rating$1.25$13.00Buy$0.0000.00% ROISNTISenti Biosciences5/2/2025Reiterated Rating$3.25$12.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics4/9/2025Initiated Coverage$20.51$50.00Buy$000.0000.00% ROILXEOLexeo Therapeutics4/8/2025Lower Price Target$1.79$22.00Buy$0.0000.00% ROILXEOLexeo Therapeutics3/25/2025Reiterated Rating$4.09$25.00Buy$0.0000.00% ROIIPSCCentury Therapeutics3/24/2025Lower Price Target$0.56$7.00Buy$0.0000.00% ROIIMRXImmuneering3/24/2025Reiterated Rating$1.80$13.00Buy$0.0000.00% ROIPRMEPrime Medicine3/20/2025Boost Price Target$2.00$16.00Buy$0.0000.00% ROITNYATenaya Therapeutics3/12/2025Lower Price Target$0.54$9.00Buy$0.0000.00% ROISLDBSolid Biosciences3/7/2025Reiterated Rating$5.42$16.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics3/4/2025Lower Price Target$4.14$28.00Buy$0.0000.00% ROIPASGPassage Bio3/4/2025Lower Price Target$8.51$120.00Buy$0.0000.00% ROIIOVAIovance Biotherapeutics3/3/2025Lower Price Target$4.24$30.00Buy$0.0000.00% ROIPRMEPrime Medicine3/3/2025Reiterated Rating$2.52$15.00Buy$0.0000.00% ROIRCKTRocket Pharmaceuticals2/28/2025Lower Price Target$9.49$54.00Buy$0.0000.00% ROINTLAIntellia Therapeutics2/28/2025Lower Price Target$9.92$68.00Buy$00.0000.00% ROITSHATaysha Gene Therapies2/26/2025Reiterated Rating$1.62$7.00Buy$0.0000.00% ROIKRYSKrystal Biotech2/20/2025Boost Price Target$176.17$218.00Buy$000.0000.00% ROISLDBSolid Biosciences2/19/2025Boost Price Target$5.30$16.00Buy$0.0000.00% ROICRSPCRISPR Therapeutics2/13/2025Lower Price Target$43.30$84.00Buy$00.0000.00% ROIFDMT4D Molecular Therapeutics2/11/2025Lower Price Target$5.32$30.00Buy$0.0000.00% ROICRGXCARGO Therapeutics1/30/2025Downgrade$13.19Neutral$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James FinancialBMO Capital Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.